Use of Integrated PET/CT as a First Line Staging and Re-staging Technique in Oncologic Patient.
NCT06168877 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2023-12-13
Summary
Positron emission tomoscintigraphy (PET) and contrast computed tomography (CTmdc) are diagnostic methods widely used in the staging and restaging of neoplastic diseases. In recent years, PET tomographs have been implemented, integrating a CT scanner into the PET tomograph (PET/CT): these tomographs are able to simultaneously acquire the function/metabolism study (PET) and the morgfostructural study (CT).
Numerous clinical studies have demonstrated the added diagnostic value of PET/CT compared to PET with consequent effect on the choice of treatment type. In addition to the potential clinical value deriving from the simultaneous execution of the two diagnostic methods, it is necessary to consider the possibility of a reduction in indirect costs deriving from the reduction of days of work lost and costs related to transport, both for the patient and for any companions.
The aims of this multicenter observational study are:
1. evaluate the diagnostic accuracy of PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer).
2. evaluate any psychological, quality of life and economic benefits deriving from carrying out the two diagnostic procedures in a single examination session.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Execution of 18F-FDG PET/CT and contrast-enhanced CT scan.
PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer).
Sponsors & Collaborators
-
IRCCS San Raffaele
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-10-21
- Primary Completion
- 2014-07-03
- Completion
- 2014-07-03
More Related Trials
-
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms
NCT06791226 ·Status: RECRUITING ·Phase: NA
-
T-Cell PET Imaging With [18F]F-AraG in Lung Cancer
NCT03311672 ·Status: WITHDRAWN ·Phase: PHASE2
-
F-18 FDG PET/CT and CT in Initial Staging of Non-small Lung Cancer
NCT06789562 ·Status: NOT_YET_RECRUITING
-
Comparing 18F-FAPI-04 and 18F-FDG PET/CT in Cancer Detection
NCT06206642 ·Status: COMPLETED ·Phase: NA
-
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
NCT06608160 ·Status: RECRUITING
-
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
NCT02817945 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
FDG PET/CT in Lung Cancer Staging
NCT02738398 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors
NCT07128277 ·Status: NOT_YET_RECRUITING
-
PET/CT-Based Image Analysis and Machine Learning of Hypermetabolic Pulmonary Lesions
NCT06602674 ·Status: COMPLETED
-
Monocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Cancer
NCT06167629 ·Status: RECRUITING
-
Diagnostic Comparison of PET-magnetic Resonance and PET-CT in Patients With Oncologic Diseases
NCT02316431 ·Status: COMPLETED
-
PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells
NCT05176275 ·Status: UNKNOWN ·Phase: NA
-
Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
NCT04253574 ·Status: COMPLETED
-
Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study
NCT00686465 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.
NCT06159920 ·Status: RECRUITING
-
Imaging Correlates of Renal Cell Carcinoma Biological Features
NCT01665703 ·Status: COMPLETED ·Phase: NA
-
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
NCT06082492 ·Status: RECRUITING ·Phase: NA
-
Integrin αvβ6-targeted PET in Malignant Tumors
NCT05835570 ·Status: RECRUITING
-
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
NCT06597526 ·Status: RECRUITING
-
Wholebody MRI In Lung Cancer StagiNg
NCT02716051 ·Status: COMPLETED ·Phase: NA
-
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
NCT06084767 ·Status: RECRUITING ·Phase: NA
-
18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer
NCT01636674 ·Status: UNKNOWN ·Phase: NA
-
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
NCT05662540 ·Status: RECRUITING ·Phase: NA
-
CD70-targeted immunoPET Imaging of Malignant Cancers
NCT06852638 ·Status: RECRUITING ·Phase: PHASE2
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA